CGRP Education & Research Forum https://validator.w3.org/feed/docs/rss2.html CGRP provokes headache in idiopathic intracranial hypertension Welcome to CGRP Forum Interventional, open-label, fixed-dose multiple administration study to evaluate long-term treatment with eptinezumab in patients with chronic cluster headache (NCT05064397) Interventional, randomized, double-blind, parallel-group, placebo-controlled study of add-on eptinezumab treatment to brief educational intervention for the preventive treatment of migraine in patients with dual diagnosis of migraine and medication overuse headache (MOH) (NCT05452239) A study with eptinezumab in adolescents (12-17 years) with chronic migraine (PROSPECT-2) (NCT04965675) Eptinezumab in patients with episodic cluster headache (ALLEVIATE) (NCT04688775) Eptinezumab as preventive treatment of migraine in adults with migraine (Sunrise) (NCT04921384) Eptinezumab in adults with migraine and medication overuse headache (Sunlight) (NCT04772742) Welcome to CGRP Forum Fremanezumab in children with chronic migraine Welcome to CGRP Forum Top-line PROCEED data support anti-PACAP mAb in migraine prevention Bridging CGRP mAbs with gepants: An innovative approach to address the wearing-off phenomenon Encouraging data for novel TRPM8-targeting agent Bocunebart reduces monthly migraine days Primary care barriers to gepant prescribing Benefits of adding atogepant to onabotulinumtoxinA for chronic migraine Eptinezumab improves migraine-related cognitive symptoms Anti-CGRP mAbs and increased miscarriage risk NICE recommends Vydura (rimegepant) in acute migraine treatment Aquipta (atogepant) receives EU approval for acute migraine treatment Weight loss with atogepant in patients with CV risk factors Combining onabotulinumtoxinA and anti-CGRP therapies in migraine prevention ECLIPSE data support atogepant for acute migraine treatment New insights on hypertension risk with anti-CGRP therapies Pilot study supports rimegepant in cluster headache AHS proposes annual migraine screening for women Rimegepant improves migraine in adolescents Welcome to CGRP Forum Peter Goadsby A multicentre, randomised, double blind, placebo controlled, parallel-group study comparing the efficacy, safety and tolerability of subcutaneous administration of fremanezumab versus placebo for the preventive treatment of episodic migraine in paediatric patients 6-17 years of age (SPACE, NCT04458857) SYNERGY real world data show benefits of combining atogepant with onabotulinumtoxinA 2025: Spotlight on advances in migraine care Lu AG09222 well tolerated with ubrogepant False non-responders can benefit from CGRP mAbs given time CGRP in the Journals Governance US prescription claims data highlight anti-CGRP therapy switching rates David Dodick Meetings Norwegian registry reports effects of CGRP mAb exposure during pregnancy Redefining a migraine day to reduce variability Should patients switch to a CGRP mAb or a gepant? UNION study confirms ubrogepant efficacy with CGRP mAbs CGRP mAb experience at a major UK centre Assessing the safety and efficacy of utilizing CGRP mAb fremanezumab in chronic migraine patients currently on monotherapy onabotulinumtoxinA (COACT) (NCT05724771) Study of oral atogepant tablets to assess safety and efficacy in adult participants with migraine (ATO ACUTE/ECLIPSE, NCT06241313) Phase 3 study of oral atogepant to assess adverse events and change in disease activity in adult participants with menstrual migraine (ATO MM, NCT06806293) Comparative effectiveness of migraine preventive medications (APT, NCT06972056) Real world data show sustained CGRP mAb benefits at three years